Valuation: AnaptysBio, Inc.

Market Cap 1.97B 1.73B 1.59B 1.47B 2.79B 188B 2.84B 19.03B 7.46B 92.62B 7.4B 7.24B 319B P/E 2026 *
-269x
P/E 2027 * 16.8x
Enterprise Value 1.88B 1.65B 1.52B 1.4B 2.66B 179B 2.7B 18.14B 7.11B 88.29B 7.06B 6.9B 304B EV / Sales 2026 *
17.1x
EV / Sales 2027 * 10.9x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day-0.30%
1 week+4.68%
Current month-1.64%
1 month+27.43%
3 months-5.29%
6 months+48.62%
Current year+36.94%
1 week 60.94
Extreme 60.94
68.6
1 month 54.3
Extreme 54.3001
69.27
Current year 42
Extreme 42
73.3
1 year 17.11
Extreme 17.1062
73.3
3 years 12.21
Extreme 12.21
73.3
5 years 12.21
Extreme 12.21
73.3
10 years 10
Extreme 10
134
Manager TitleAgeSince
Chief Executive Officer 46 2022-03-20
Director of Finance/CFO 42 2026-05-10
Corporate Officer/Principal 35 2021-12-31
Director TitleAgeSince
Director/Board Member 79 2015-06-29
Director/Board Member 63 2015-06-29
Director/Board Member 49 2021-04-07
Date Insider Type Main position Quantity % Market Cap.
06-14Fiscal year

Director

12,060 0.0414%
06-14Fiscal year

Director

12,060 0.0414%
06-14Fiscal year

Chairman

12,060 0.0414%
Change 5-day change 1-year change 3-year change Capi.($)
-0.30%+4.68%+154.47%+223.07% 1.97B
-4.14%-8.06%+57.35%+117.24% 56.98B
+1.84%+1.65%+76.90%+95.68% 53.58B
-2.24%+3.59%+19.60%+466.72% 25.63B
-1.60%-6.21%-19.69%-14.84% 23.51B
+2.43%+1.06%+47.70%-0.11% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+195.12%+357.18% 16.46B
+8.74%+3.51%+53.81% - 14.13B
-1.05%+1.16%+25.08%+196.28% 14.35B
Average -0.63%+1.55%+64.43%+157.15% 24.42B
Weighted average by Cap. -1.01%+0.33%+55.73%+139.40%

Financials

2026 *2027 *
Net sales 110M 96.36M 88.85M 82.1M 156M 10.49B 158M 1.06B 416M 5.17B 413M 404M 17.78B 154M 135M 124M 115M 217M 14.65B 221M 1.48B 581M 7.22B 577M 564M 24.84B
Net income -7.47M -6.54M -6.03M -5.57M -10.57M -712M -10.74M -72.06M -28.26M -351M -28.03M -27.43M -1.21B 129M 113M 104M 96.08M 182M 12.28B 185M 1.24B 487M 6.05B 483M 473M 20.81B
Net Debt -92.22M -80.8M -74.5M -68.84M -131M -8.8B -133M -890M -349M -4.33B -346M -339M -14.91B -293M -257M -237M -219M -415M -27.95B -422M -2.83B -1.11B -13.77B -1.1B -1.08B -47.38B
Logo AnaptysBio, Inc.
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
Employees
104
Date Price Change Volume
26-07-10 US$66.39 -0.30% 400,960
26-07-09 US$66.59 +1.90% 394,336
26-07-08 US$65.35 -2.93% 1,164,820
26-07-07 US$67.33 +8.05% 947,775
26-07-06 US$62.31 -1.75% 559,584
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
66.59USD
Average target price
87.09USD
Spread / Average Target
+30.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANAB Stock